Triple vs. dual therapy in patients with COPD: systematic review and meta-analysis
Introduction: There is uncertainty about the best risk-benefit profile for treatment with triple therapy in patients with COPD. Objective: Identify the available scientific evidence on the effectiveness and safety of triple therapy compared to dual therapy in patients with COPD. Method: A systematic review of the literature was conducted according to the Cochrane methodology using the Medline, Embase and Central databases. Results: Acute exacerbations were evaluated in six studies, rate ratio of 0.74 (0.68-0.81), representing a reduction of 26% and mortality was evaluated in six studies showing a decrease of 29%, relative risk of 0. 71 (0.56-0.91) with triple therapy. Pneumonia was evaluated in seven studies, showing an increase in events with triple therapy, relative risk of 1.54 (1.30-1.81). Adverse events were evaluated in ten studies with no differences found. Discussion: Triple therapy reduced exacerbations and mortality consistent with what was described in previous reviews. Adverse events were similar between both therapies. An increase in pneumonia episodes, a worsening of dyspnea and FEV1 was found with the use of triple therapy . Conclusion: Triple therapy is an important alternative in patients with persistent exacerbations and highly symptomatic despite dual therapy. It is a safe therapy, but the occurrence of pneumonia must be monitored specifically.
Authors
- Carolina Ocampo-Salgado
- Juan José Yepes-Núñez (ORCID: https://orcid.org/0000-0002-9912-0031)
- Sebastián Castaño-Duque (ORCID: https://orcid.org/0009-0001-8635-8243)
- Diana M. Chaparro-Martínez
- Andrés F. Rodríguez-Gutiérrez
- Olga M. García-Molares
- Jorge E. Rivas-IbarguÓen
- Fredy L. Carreño
Publication Details
- Journal
- NCT Neumología y Cirugía de Tórax (English Edition)
- Published
- 2026-11-17
- DOI
- https://doi.org/10.24875/ncte.m25000037
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00